Evolus, Inc. (EOLS)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$9.30+2.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
Intact: The reason to own it still holds.
Evolus aims for $327M to $337M revenue in 2026. It plans a low- to mid-single digit profit margin. The company beat earnings recently. These show progress in a tough market.
Evolus is still losing money. It missed earnings twice this year. Revenue growth may slow and hurt the turnaround.
The market expects about 18% revenue growth. Our fair value is near $26.40, close to consensus. We see risk in profitability and growth execution.
Breaks if: Adjusted EBITDA margin falls below low single digits in FY26
Maintain disciplined expense management to achieve low- to mid-single digit Adjusted EBITDA margin for full-year 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
EOLS represents a speculative growth investment with a focus on expanding its product portfolio. The current thesis state is intact, supported by recent revenue growth and strategic initiatives, but it faces risks related to market conditions and execution.
The market appears to price EOLS as a company with a justified valuation, showing it is relatively cheap compared to peers. However, there is an expectations gap, indicating that investors may not fully anticipate the challenges or potential growth ahead.
Fundamentals are likely to show consistent revenue growth, as management has reaffirmed guidance and is focused on maintaining disciplined expense control. However, the company remains loss-making, which adds a layer of risk to its financial performance.
The long-term thesis hinges on management's ability to meet revenue guidance and achieve profitability targets. Additionally, the performance of sector bellwethers and broader economic conditions will be crucial in shaping investor sentiment and the company's future.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'mixed'.
Yes, our read has weakened. The latest earnings miss has negatively impacted the outlook for EOLS. This miss raises concerns about the company's credibility and future performance.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Non-GAAP operating expenses are guided to $212M-$216M for 2026, a modest 1%-3% increase over 2025, while Adjusted EBITDA margin is expected to be low- to mid-single digit. Management is maintaining disciplined expense control consistent with this priority.
“Reaffirms low- to mid-single digit Adjusted EBITDA margin in 2026 and narrows non-GAAP operating expenses guidance to between $212 million and $216 million.”
“Reaffirms full-year 2026 non-GAAP operating expenses of $210 million to $216 million and expects low- to mid-single digit Adjusted EBITDA margin.”
“Company continues to expect to achieve a low- to mid-single digit Adjusted EBITDA Margin in 2026.”
Breaks if: EPS remains negative in FY27
Breaks if: revenue falls below $327M in FY26
Over the next 1 to 3 years, EOLS faces a challenging environment but has potential for growth if it can execute on its strategic priorities. Not investment advice.